CoChat

Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials

Open access
Giugliano, Dario, Maiorino, Maria Ida, Bellastella, Giuseppe, Chiodini, Paolo, Esposito, Katherine · 2019 · Journal of the American Heart Association
Cited by 99

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Background: The value of glycemic control and preexisting cardiovascular disease in determining the risk of major cardiovascular events (MACE) in type 2 diabetes mellitus is uncertain. Intensive glucose control trials suggest that the 9% lower risk of MACE associated with intensive glycemic control, as compared with conventional glycemic control, is only driven by patients with type 2 diabetes mellitus without cardiovascular disease at baseline. Methods and Results: We did a meta‐analysis of cardiovascular outcome trials dividing patients with or without preexisting cardiovascular disease; we found that the lower risk of MACE is confined to patients with cardiovascular disease at baseline. Compared with placebo, the use of both glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors was associated with a significant 14% lower MACE risk in patients with preexisting cardiovascular disease and with a nonsignificant 2% higher MACE risk in those without preexisting cardiovascular disease ( P for interaction=0.021). The meta‐regression analysis of all 12 trials demonstrated a significant ( P =0.002) association between reductions of glycated hemoglobin in glycated hemoglobin A 1C . Accordingly, the reduction of MACE expected if all cardiovascular outcome trials had achieved a 0.9% glycated hemoglobin reduction would have been 33%. Routine clinical care data complement the results of cardiovascular outcome trials but with some differences: the lower risk of MACE with sodium‐glucose cotransporter‐2 inhibitor use is evident in patients with type 2 diabetes mellitus with or without preexisting cardiovascular disease. Conclusions: Sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists should be included in the therapeutic plan of patients with type 2 diabetes mellitus and overt cardiovascular disease, with due attention paid to improvement of glycemic control, which may amplify their benefit on MACE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.119.012356

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 18

  1. 10.1161/CIRCULATIONAHA.117.027252 · DOI
  2. 10.2337/dc16-1974 · DOI · Paper page
  3. 10.7326/0003-4819-151-4-200908180-00136 · DOI · Paper page
  4. 10.2337/dc12‐0336 · DOI · Paper page
  5. 10.2337/dc16-1957 · DOI · Paper page
  6. 10.1136/bmj.d5928 · DOI · Paper page
  7. 10.1136/bmj.315.7109.629 · DOI · Paper page
  8. 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  9. 10.1007/s12020‐017‐1517‐9 · DOI
  10. 10.1111/dom.13629 · DOI · Paper page
  11. 10.1056/NEJMoa1612917 · DOI · Paper page
  12. 10.2337/dc17-2677 · DOI · Paper page
  13. 10.1111/dom.13581 · DOI
  14. 10.1161/CIRCULATIONAHA.117.031227 · DOI · Paper page
  15. 10.1016/S2213‐8587(18)30320‐6 · DOI · Paper page
  16. 10.1111/dom.13477 · DOI · Paper page
  17. 10.1111/dom.13612 · DOI · Paper page
  18. 10.2337/dc17-1223 · DOI · Paper page

Cited by

See all 99

Metadata

Authors
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K.
Venue
Journal of the American Heart Association
Published
2019-06-18
Volume
8
Issue
12
Pages
e012356-e012356
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2948602156
Cited by
99
References
28
FWCI
3.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. https://app.cochat.ai/papers/10.1161/jaha.119.012356
The paper
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2019). Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. Journal of the American Heart Association. https://doi.org/10.1161/jaha.119.012356

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.